Predictors of olaparib discontinuation owing to adverse drug events in patients with ovarian, peritoneal, or fallopian tube cancer: a retrospective observational study

• DOI: 10.1080/1120009x.2024.2345025
• Publication Date: 2024-05-02T13:29:40Z
• Authors: Noriaki Kataoka; Takeo Hata; Kouichi Hosomi; Atsushi Hirata; Satoe Fujiwara; Emi Goto; Masami Nishihara; Masahide Ohmichi; Masashi Neo
• Keywords: Fallopian tube; Discontinuation; Olaparib; Fallopian tube cancer

We investigated predictors of olaparib discontinuation owing to adverse effects. Patients with ovarian, peritoneal, or fallopian tube cancers treated at Osaka Medical and Pharmaceutical University Hospital between April 2018 September 2022 were included in this study. The exclusion criteria as follows: treatment due disease progression, use anaemia medications, cytochrome P450 (CYP3A4) inhibitors. follow-up period was 90 d. Of the 46 eligible patients, 21 patients discontinued olaparib, including 15 grade 3 higher anaemia, eight neutropenia, four non-haematological toxicity (including multiple onset). Multivariate logistic regression analysis showed that 4 neutropenia progression grades 2-3 chemotherapy administered before administration discontinuation. severity may be a potential marker for its